International Alliance for Cancer Early Detection (ACED)
The University of Manchester is a part of the International Alliance for Cancer Early Detection (ACED). Launched in 2019 and successfully renewed in 2025, ACED is a £50 million partnership between Cancer Research UK, The University of Manchester, University College London (UCL), the Knight Cancer Institute at OHSU, the University of Cambridge, Dana Farber Cancer Institute, and the German Cancer Research Center.
Over the next five years, the the Alliance will commit a further £50m in funding to accelerate cutting-edge research in four major programmatic areas – immunology, hereditary cancers, inequalities, and interception.
Each of the four ACED research themes are supported by a patient advocacy champion, bringing patients and the public into the heart of cancer early detection research.
Navigation
About ACED Manchester
ACED is a £55 million partnership between world-leading early detection institutes and organisations dedicated to improving the early detection of cancer.
Research Themes
ACED Manchester's research is prioritised across three key research themes and several disease sites.
Training and Development
A core goal at ACED Manchester is to enable the next-generation of early detection research scientists to become future leaders.
Funding Opportunities
Discover the opportunities for ACED Member organisations to lever additional ACED funding in strategic areas.
Funding Acknowledgements
Access the Communications Toolkit for researchers, students and projects funded through ACED
CRUK Manchester Centre
Navigate back to the CRUK Manchester Centre homepage